
Axsome Therapeutics presents new migraine treatment data at AHS 2026 meeting.
Axsome Therapeutics showcased new clinical data on SYMBRAVO, their migraine treatment combining meloxicam and rizatriptan, at the American Headache Society's 68th Annual Scientific Meeting. The presentations covered efficacy, safety, and comparative ...

